NCT04850599View on ClinicalTrials.gov

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

April 15, 2026

Study Completion Date

February 21, 2029

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Carfilzomib

Given IV

BIOLOGICAL

Isatuximab

Given IV

DRUG

Pomalidomide

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Sanofi

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT04850599 - Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter